{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:44:58Z","timestamp":1761101098857},"reference-count":37,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T00:00:00Z","timestamp":1362700800000},"content-version":"vor","delay-in-days":9320,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[1987,9]]},"abstract":"<jats:p>Two controlled clinical studies evaluated the effects of phenylpropanolamine HCL (PPA) on measures of blood pressure, pulse, and subjective state (mood). One hundred fifty subjects participated in a parallel groups design that compared a 75\u2010mg sustained release (SR) preparation with a 25\u2010mg tid. dosing regimen and placebo. Fifty\u2010nine of these subjects participated in an additional cross\u2010over component that compared SR PPA 75 mg with placebo. Measures of blood pressure, pulse, and subjective drug effect were obtained nine times throughout the course of a 12\u2010hour session. Data analysis revealed no clinically and few statistically significant effects due to drug treatment. As expected, most measures showed circadian changes on both the cardiovascular and mood variables, which were not related to drug treatment. No euphorogenic or \u201camphetaminelike\u201d effects were noted. Although further work is warranted regarding the effects of chronic or higher\u2010than\u2010normal doses of PPA, the current studies suggest that PPA, at currently recommended dose levels, is not associated with adverse effects on either cardiovascular or subjective functioning.<\/jats:p>","DOI":"10.1002\/j.1552-4604.1987.tb03089.x","type":"journal-article","created":{"date-parts":[[2013,3,9]],"date-time":"2013-03-09T00:14:54Z","timestamp":1362788094000},"page":"685-693","source":"Crossref","is-referenced-by-count":24,"title":["Phenylpropanolamine: Effects on Subjective and Cardiovascular Variables at Recommended Over\u2010the\u2010Counter Dose Levels"],"prefix":"10.1002","volume":"27","author":[{"given":"Ira","family":"Liebson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Bigelow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland R.","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank R.","family":"Funderburk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,8]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"8466","article-title":"Weight control drug products for over\u2010the\u2010counter human use: Establishment of a monograph","volume":"47","year":"1982","journal-title":"Federal Register"},{"key":"e_1_2_1_3_2","first-page":"38312","article-title":"Over\u2010the\u2010counter drugs: Establishment of a monograph for OTC cold\u2010cough, allergy, broncodilator and antiasthmatic drug products","volume":"41","year":"1976","journal-title":"Federal Register"},{"key":"e_1_2_1_4_2","first-page":"22912","article-title":"Over\u2010the\u2010counter oral health care and discomfort drugs: Establishment of a monograph","volume":"47","year":"1982","journal-title":"Federal Register"},{"key":"e_1_2_1_5_2","first-page":"40298","article-title":"Cough, cold, asthma, broncodilator and allergy panel report","volume":"47","year":"1982","journal-title":"Federal Register"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1982.03320290010007"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(80)90490-0"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1981.03310310043020"},{"key":"e_1_2_1_9_2","first-page":"13","volume-title":"Phenylpropanolamine: A critical analysis of reported adverse reactions and overdosage.","author":"Morgan JP","year":"1986"},{"key":"e_1_2_1_10_2","first-page":"115","article-title":"Therapeutic doses of phenylpropanolamine increase supine systolic blood pressure","volume":"9","author":"Pentel PR","year":"1985","journal-title":"Int J Obesity"},{"key":"e_1_2_1_11_2","first-page":"343","volume-title":"Phenylpropanolamine: Risks, Benefits and Controversies.","author":"Smith DE","year":"1985"},{"key":"e_1_2_1_12_2","first-page":"35344","article-title":"Anonymous: new drug status of OTC combination drugs containing caffeine, phenylpropanolamine and ephedrine","volume":"47","year":"1982","journal-title":"Federal Register"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1981.03310380050029"},{"key":"e_1_2_1_14_2","first-page":"8","article-title":"PPA\u2014Phenylpropanolamine: An adjunct to weight control management","volume":"58","author":"Silverman HI","year":"1984","journal-title":"NY State Pharm"},{"key":"e_1_2_1_15_2","first-page":"163","volume-title":"Advances in Behavioral Pharmacology","author":"Griffiths RR","year":"1979"},{"key":"e_1_2_1_16_2","first-page":"383","volume-title":"Phenylpropanolamine: Risks, Benefits, and Controversies.","author":"Winick C","year":"1985"},{"key":"e_1_2_1_17_2","first-page":"185","article-title":"Lack of side effects from orally administered phenylpropanolamine with caffeine: A controlled three phase study","volume":"28","author":"Silverman HI","year":"1980","journal-title":"Cur Ther Res"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1986.153"},{"key":"e_1_2_1_19_2","first-page":"47","article-title":"Possible cardiovascular effects of phenylpropanolamine and belladonna alkaloids","volume":"10","author":"Mitchell CA","year":"1968","journal-title":"Cur Ther Res"},{"key":"e_1_2_1_20_2","first-page":"535","article-title":"A double\u2010blind clinical evaluation of a phenylpropanolamine\u2010caffeine\u2010vitamin combination and placebo in the treatment of exogenous obesity","volume":"17","author":"Griboff SI","year":"1975","journal-title":"Cur Ther Res"},{"key":"e_1_2_1_21_2","first-page":"549","article-title":"Three controlled trials of weight loss with phenylpropanolamine","volume":"6","author":"Altschuler S","year":"1982","journal-title":"Int J Obesity"},{"key":"e_1_2_1_22_2","first-page":"81","article-title":"An estimation of the toxicity of nonprescription diet aids from seventy exposure cases","volume":"25","author":"Ekins BR","year":"1983","journal-title":"Vet Hum Toxicol"},{"key":"e_1_2_1_23_2","volume-title":"Recommendations for Human Blood Pressure Determination by Sphygmomanometers: Report on the Postgraduate Education Committee, American Heart Association.","author":"Kirkendall WM","year":"1980"},{"key":"e_1_2_1_24_2","volume-title":"Overview of Addiction Research Center's Scales (ARCI): An Appendix and Manual of Scales.","author":"Haertzen CA","year":"1974"},{"key":"e_1_2_1_25_2","volume-title":"Methods for Assessing the Reinforcing Properties of Abused Drugs.","author":"Haertzen CA"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-6147(84)90415-2"},{"key":"e_1_2_1_27_2","volume-title":"EDITS Manual for the Profile of Mood States.","author":"McNair DM","year":"1971"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1214\/aoms\/1177706545"},{"key":"e_1_2_1_29_2","first-page":"357","volume-title":"Statistical power analysis for the behavioral sciences.","author":"Cohen J","year":"1969"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(81)90001-5"},{"key":"e_1_2_1_31_2","volume-title":"Antihypertensive Therapy: Principles and Practice: An International Symposium.","author":"Bock KD","year":"1966"},{"key":"e_1_2_1_32_2","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1001\/jama.1982.03320320028025","article-title":"Blood pressure during normal daily activities, sleep, and exercise: Comparison of values in normal and hypertensive subjects","volume":"247","author":"Pickering TG","year":"1982","journal-title":"JAMA"},{"key":"e_1_2_1_33_2","first-page":"450","article-title":"Variation in arterial pressure throughout the day and night","volume":"26","author":"Richardson DW","year":"1964","journal-title":"Clin Sci"},{"key":"e_1_2_1_34_2","first-page":"22","volume-title":"The hypertensive patient.","author":"Rose G","year":"1980"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1981.tb01198.x"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.333584"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1037\/h0026861"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1985.03350410037006"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fj.1552-4604.1987.tb03089.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/j.1552-4604.1987.tb03089.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T17:14:56Z","timestamp":1697908496000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/j.1552-4604.1987.tb03089.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1987,9]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[1987,9]]}},"alternative-id":["10.1002\/j.1552-4604.1987.tb03089.x"],"URL":"https:\/\/doi.org\/10.1002\/j.1552-4604.1987.tb03089.x","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[1987,9]]}}}